Champions Oncology Inc (NASDAQ:CSBR) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.42.
Several equities research analysts have recently issued reports on CSBR shares. Benchmark started coverage on shares of Champions Oncology in a research note on Wednesday, November 27th. They set a “buy” rating and a $11.00 price target for the company. Roth Capital started coverage on shares of Champions Oncology in a research note on Friday, September 20th. They set a “buy” rating and a $9.25 price target for the company. Zacks Investment Research upgraded shares of Champions Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, ValuEngine upgraded shares of Champions Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 7th.
A number of institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP grew its stake in Champions Oncology by 51.0% in the 2nd quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 8,279 shares in the last quarter. Marshall Wace LLP purchased a new position in Champions Oncology in the 1st quarter valued at approximately $99,000. Alambic Investment Management L.P. grew its stake in Champions Oncology by 27.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 14,614 shares in the last quarter. BlackRock Inc. grew its stake in Champions Oncology by 12.0% in the 2nd quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock valued at $1,073,000 after buying an additional 14,733 shares in the last quarter. Finally, Tocqueville Asset Management L.P. grew its stake in Champions Oncology by 69.1% in the 3rd quarter. Tocqueville Asset Management L.P. now owns 134,568 shares of the biotechnology company’s stock valued at $760,000 after buying an additional 55,000 shares in the last quarter. Institutional investors and hedge funds own 49.33% of the company’s stock.
Shares of CSBR stock traded up $0.21 during trading hours on Tuesday, hitting $8.39. 88,200 shares of the company were exchanged, compared to its average volume of 35,333. The firm has a fifty day simple moving average of $7.39 and a 200 day simple moving average of $6.50. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 1.62. Champions Oncology has a 52-week low of $4.98 and a 52-week high of $12.80. The stock has a market capitalization of $94.94 million, a price-to-earnings ratio of 839.00 and a beta of 1.27.
Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Monday, December 16th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.04. Champions Oncology had a negative net margin of 3.35% and a negative return on equity of 45.46%. The company had revenue of $7.63 million during the quarter, compared to analyst estimates of $7.83 million. Sell-side analysts anticipate that Champions Oncology will post 0.03 EPS for the current year.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
See Also: How does a dividend reinvestment plan work?
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.